NEUROCRINE BIOSCIENCES INC Deferred Income Tax Expense (Benefit)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Deferred Income Tax Expense (Benefit) of $164.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC deferred income tax expense (benefit) for fiscal 2025 was $164.20M.
- NEUROCRINE BIOSCIENCES INC deferred income tax expense (benefit) for fiscal 2024 was -$123.00M.
- NEUROCRINE BIOSCIENCES INC deferred income tax expense (benefit) for fiscal 2023 was -$60.70M, a 375.91% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC deferred income tax expense (benefit) for fiscal 2022 was $22.00M, a 300.00% increase from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $164.20M 10-K · filed 2026-02-11 |
| 2024-12-31 | -$123.00M 10-K · filed 2026-02-11 |
| 2023-12-31 | -$60.70M 10-K · filed 2026-02-11 |
| 2022-12-31 | $22.00M 10-K · filed 2025-02-10 |
| 2021-12-31 | $5.50M 10-K · filed 2024-02-09 |
| 2020-12-31 | -$310.70M 10-K · filed 2023-02-09 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-11 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |